Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.

[1]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[2]  M. Mandelkern,et al.  Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. , 1996, American journal of respiratory and critical care medicine.

[3]  R. Arriagada,et al.  Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. , 1994, Lung cancer.

[4]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[5]  P. Rubin,et al.  International Clinical Trials in Radiation Oncology. The late effects of toxicity scoring. , 1988, International journal of radiation oncology, biology, physics.

[6]  R K Ten Haken,et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Rosenzweig,et al.  Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[8]  P. Rubin,et al.  The late effects of toxicity scoring , 1988 .

[9]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Nackaerts,et al.  Lymph node mapping in non-small cell lung cancer with FDG-PET scan: a prospective study in 690 LN levels from 68 patients , 1997 .

[11]  T. Naruke,et al.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer. , 1978, The Journal of thoracic and cardiovascular surgery.

[12]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Henk Kramer,et al.  Current Concepts in the Mediastinal Lymph Node Staging of Nonsmall Cell Lung Cancer , 2003, Annals of surgery.

[14]  P. Maguire,et al.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.

[15]  K. Kostikas,et al.  Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. , 2004, Lung cancer.

[16]  O. Hansen,et al.  The location of recurrences in patients with non-small cell lungcancer treated with involved-field irradiation , 2000 .

[17]  Icru.  Prescribing, recording, and reporting photon beam therapy , 1993 .

[18]  Ludy Lutgens,et al.  Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. , 2005, International journal of radiation oncology, biology, physics.

[19]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[20]  M. Satouchi,et al.  Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[21]  L. Boersma,et al.  Interim analysis of a phase I/II dose escalation trial in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiotherapy (3D-CRT) , 2001 .

[22]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Vansteenkiste,et al.  The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. , 2001, The European respiratory journal.

[24]  L. Boersma,et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  C. Ling,et al.  Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. , 2000, Cancer journal.

[26]  F. Maes,et al.  FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? , 1998, European Journal of Nuclear Medicine.

[27]  Douglas L. Jones.  ICRU Report 50—Prescribing, Recording and Reporting Photon Beam Therapy , 1994 .

[28]  R. V. van Klaveren,et al.  Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[29]  M. Graham,et al.  The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. , 2003, Lung cancer.

[30]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[31]  M. Martel,et al.  186 Incidental dose to clinically negative nodes from conformal treatment fields for nonsmall cell lung cancer , 1999 .

[32]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[33]  M. Sasaki,et al.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography , 1996, European Journal of Nuclear Medicine.

[34]  S. Dische,et al.  From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[35]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.